LEM Surgical is building a next-generation robotic surgery platform aimed at surpassing existing systems for spine procedures. The company is advancing product development to ready a robotic system for FDA submission in the second half of 2024. Financially, LEM Surgical completed a €23.6 million Series B that was strongly oversubscribed. The funding comes from new investors in both the United States and Switzerland and is earmarked to accelerate development and regulatory readiness. LEM Surgical was founded in 2021 and is headquartered in Bern, Switzerland. Its founding team includes Prof. Dr. Stefan Weber, Marco Matulic, Simon Michel, Prof. Dr. Andreas Raabe and Yossi Bar. LEM Surgical develops surgical robotic solutions focused on spinal and orthopaedic surgery. The company raised CHF 8.7M in a Series A to advance its product development. Proceeds will be used to further develop the product and prepare documentation for submission to the U.S. FDA in early 2024. LEM was founded in June 2021 and is based in Bern, Switzerland. Its founding team includes Stefan Weber (CEO, CAScination AG), Andreas Raabe (Director, Department of Neurosurgery, Inselspital Bern), Marco Matulic (CTO, CAScination AG), Simon Michel (CEO, Ypsomed Group) and Yossi Bar (previously Director R&D at Mazor Robotics Ltd., which was sold to Medtronic in 2018). The company aims to deliver solutions for patients in the field of orthopaedic and especially spinal surgery.

Total raised

$35M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2024